AQUIS EXCHANGE PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 466 GBX | 0.00% |
|
+0.22% | +27.67% |
| Apr. 24 | EDX Medical to begin trading on Apex segment of AQSE next week | AN |
| Apr. 23 | Marula reaches "significant milestone" for Tanzanian graphite projects | AN |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With a 2023 P/E ratio at 25.6 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- With an enterprise value anticipated at 4.73 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Sector: Financial & Commodity Market Operators
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +27.67% | 157M | - | ||
| +2.05% | 77.39B | B | ||
| +23.51% | 23.92B | C+ | ||
| +25.95% | 12.26B | C+ | ||
| +0.24% | 8.13B | B- | ||
| +26.45% | 7.58B | C+ | ||
| -6.47% | 2.83B | C+ | ||
| +17.39% | 2.31B | C | ||
| -6.10% | 1.69B | C | ||
| +24.19% | 1.4B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- AQX Stock
- Ratings Aquis Exchange PLC
